Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CDC releases brief on vaccine statistics

* U.S. CDC SAYS DELIVERED 312,508,205 DOSES OF COVID-19 VACCINE AS OF MAY 1 VERSUS 308,774,155 DOSES AS OF APRIL 30

* U.S. CDC SAYS ADMINISTERED 243,463,471 DOSES OF COVID-19 VACCINE AS OF MAY 1 VERSUS 240,159,677 DOSES AS OF APRIL 30

* U.S. CDC SAYS 146,239,208 INDIVIDUALS HAVE RECEIVED AT LEAST ONE DOSE OF COVID-19 VACCINE AS OF MAY 1 VERSUS 144,894,586 INDIVIDUALS AS OF APRIL 30

* U.S. CDC SAYS 103,422,555 INDIVIDUALS HAVE BEEN FULLY VACCINATED AGAINST COVID-19 AS OF MAY 1 VERSUS 101,407,318 INDIVIDUALS AS OF APRIL 30

* U.S. CDC SAYS 7,799,933 DOSES OF COVID-19 VACCINE ADMINISTERED IN LONG-TERM CARE HOMES AS OF MAY 1 VERSUS 7,797,395 DOSES ADMINISTERED AS OF APRIL 30

Source: Reuters

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!